Coya Therapeutics stock maintains Buy rating at H.C. Wainwright on ALS trial launch

Coya Therapeutics has initiated its Phase 2 ALSTARS trial for COYA 302 in amyotrophic lateral sclerosis (ALS), following FDA Investigational New Drug (IND) acceptance and a $4.2 million milestone payment from Dr. Reddy's. This development underpins strong analyst confidence, with H.C. Wainwright reiterating a Buy rating and an $18 price target, aligning with a consensus ranging up to $20 from multiple firms. The $91.49 million market cap company, which maintains a strong financial position, is leveraging positive prior clinical data as this trial could pave the way for a registrational Phase 2/3 study.

Analysis

Coya Therapeutics (COYA) has advanced its clinical program by initiating the Phase 2 ALSTARS trial for its amyotrophic lateral sclerosis (ALS) treatment, COYA 302. This pivotal event follows the U.S. Food and Drug Administration's acceptance of its Investigational New Drug (IND) application, a regulatory milestone that triggered a $4.2 million payment from partner Dr. Reddy’s Laboratories. Financially, the $91.49 million market capitalization company is positioned strongly, with a reported current ratio of 7.43 and a balance sheet holding more cash than debt. The initiation of this multi-center, double-blind, placebo-controlled study underpins a wave of bullish analyst sentiment. H.C. Wainwright reiterated its Buy rating and an $18.00 price target, representing substantial upside from the current $5.47 price. This view is shared across the street, with firms like Lucid Capital Markets, BTIG, and Lake Street Capital issuing price targets ranging from $15.00 to $20.00. The trial's success is seen as a crucial step toward a potentially registrational Phase 2/3 study, making its progress the central value driver for the company.

Key Decisions for Investors

• Given the strong analyst consensus with price targets significantly above the current stock price, investors may view the initiation of the Phase 2 trial as a key de-risking event and a potential entry point.
• Investors should recognize that as a clinical-stage biotech firm, Coya's value is almost entirely dependent on the trial outcome for COYA 302, representing a high-risk, high-reward profile.
• The company's strong financial position with a net cash balance mitigates immediate dilution risk, but monitoring cash burn throughout the resource-intensive trial will be critical for assessing long-term financing needs.
• Mark September 29, 2025, on the calendar, as the presentation of further study details on this date represents the next identifiable catalyst that could impact the stock's valuation.